LABU: The Risks And Rewards Of A Leveraged Biotechnology ETF
Source: SeekingAlpha
2025-12-17 12:29:56 ET
Fast Facts About the Direxion Daily S&P Biotech Bull 3X ETF
Read the full article on Seeking Alpha
For further details see:
LABU: The Risks And Rewards Of A Leveraged Biotechnology ETF
Avidity Biosciences Inc.
NASDAQ: RNA
RNA Trading
0.41% G/L:
$14.84 Last:
323,876 Volume:
$14.70 Open:
RNA Latest News
February 27, 2026 09:19:00 am
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
February 26, 2026 04:02:00 pm
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
February 23, 2026 08:00:00 am
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
RNA Stock Data
$10,978,987,941
124,608,839
0.38%
98
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
